RESUMEN
La PET con análogos de la somatostatina permite detectar aquellas células con sobreexpresión de receptores de somatostatina, especialmente del subtipo 2 y 5, siendo variable esta detección según el tipo de molécula que se utilice. Esta es la base para su uso en el estudio de los tumores neuroendocrinos (NET), los cuales se caracterizan por presentar una sobreexpresión de estos receptores en más del 80% de los subtipos. Esta PET llega a nuestro país avalada por los buenos resultados publicados por otros grupos, superiores a los de otras técnicas de imagen. Presentamos dos de los primeros casos de PET con análogos de la somatostatina: 68Ga-edetreótida (SomaKit TOC(R)) realizados en nuestro centro. La PET fue la prueba que determinó finalmente el manejo clínico de ambos pacientes
PET with somatostatin analogues (SSA PET/CT) enables the detection of cells with overexpression of somatostatin receptors, especially subtypes 2 and 5; this detection is variable depending on the type of molecule used. This is the basis for its use in the study of neuroendocrine tumours (NETs), which are characterized by an overexpression of these receptors in more than 80% of the subtypes. This PET is now being used in our country supported by the good results published by other groups, that were superior to those of other imaging techniques. We present two of the first cases of SSA-PET/CT with 68Ga-edotreotide (SomaKit TOC(R)) performed in our centre. SSA-PET/CT was the test that finally determined the clinical management of both patients
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Tumores Neuroendocrinos/química , Tumores Neuroendocrinos/diagnóstico por imagen , Compuestos Organometálicos , Tomografía Computarizada por Rayos X , Receptores de Somatostatina/análisis , Somatostatina/análogos & derivados , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X/métodosRESUMEN
PET with somatostatin analogues (SSA PET/CT) enables the detection of cells with overexpression of somatostatin receptors, especially subtypes 2 and 5; this detection is variable depending on the type of molecule used. This is the basis for its use in the study of neuroendocrine tumours (NETs), which are characterized by an overexpression of these receptors in more than 80% of the subtypes. This PET is now being used in our country supported by the good results published by other groups, that were superior to those of other imaging techniques. We present two of the first cases of SSA-PET/CT with 68Ga-edotreotide (SomaKit TOC®) performed in our centre. SSA-PET/CT was the test that finally determined the clinical management of both patients.